Type 2 diabetes and treatment
Item
diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current oha (oral hypoglycaemic agent) treatment with stable dose for at least six months
boolean
C0011860 (UMLS CUI [1])
C0011878 (UMLS CUI [2])
C0359086 (UMLS CUI [3])
BMI
Item
bmi (body mass index) between 24 and 35 kg/m^2 (both inclusive)
boolean
C1305855 (UMLS CUI [1])
Fasting plasma glucose
Item
fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
boolean
C0583513 (UMLS CUI [1])
Anti-gad
Item
anti-gad (glutamic acid decarboxylase) negative
boolean
C1167898 (UMLS CUI [1])
Allergy to trial product
Item
known or suspected allergy to trial product or related products
boolean
C0020517 (UMLS CUI [1,1])
C3854006 (UMLS CUI [1,2])
Experimental drugs
Item
receipt of any investigational drug within three months prior to this trial
boolean
C0304229 (UMLS CUI [1])
Recurrent severe hypoglycaemia
Item
recurrent severe hypoglycaemia as judged by the investigator
boolean
C0342316 (UMLS CUI [1])
Cardiac disease or ECG
Item
cardiac disease or any clinically significant abnormal ecg (electrocardiogram)
boolean
C0018799 (UMLS CUI [1])
C0013798 (UMLS CUI [2])
Pharmacotherapy and drug interactions
Item
use of any drug (except oral hypoglycaemic agents (ohas)) which in the investigator's opinion could interfere
boolean
C0013216 (UMLS CUI [1,1])
C0687133 (UMLS CUI [1,2])
Medication interferring with blood glucose level
Item
with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
boolean
C0392201 (UMLS CUI [1,1])
C0013216 (UMLS CUI [1,2])
C0687133 (UMLS CUI [1,3])
Liver or renal disease
Item
liver or renal disease
boolean
C0023895 (UMLS CUI [1])
C0022658 (UMLS CUI [2])